Becton, Dickinson and Company (NYSE:BDX) Stock Unloaded Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently sold shares of Becton, Dickinson and Company (NYSE:BDX). In a filing disclosed on April 11th, the Representative disclosed that they had sold between $15,001 and $50,000 in Becton, Dickinson and Company stock on March 5th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 3/31/2025.
• Purchased $50,001 – $100,000 in shares of Block (NYSE:XYZ) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of DuPont de Nemours (NYSE:DD) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of United Community Banks (NASDAQ:UCB) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of IDEX (NYSE:IEX) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of HNI (NYSE:HNI) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of ServiceNow (NYSE:NOW) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Coinbase Global (NASDAQ:COIN) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Constellation Energy (NASDAQ:CEG) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of Simon Property Group (NYSE:SPG) on 3/31/2025.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded up $1.40 on Wednesday, hitting $203.44. The company’s stock had a trading volume of 184,321 shares, compared to its average volume of 1,688,586. Becton, Dickinson and Company has a fifty-two week low of $193.03 and a fifty-two week high of $251.99. The company has a market capitalization of $58.41 billion, a PE ratio of 33.77, a PEG ratio of 1.63 and a beta of 0.35. The stock’s 50 day moving average is $222.67 and its 200-day moving average is $229.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 2.04%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of analyst reports. Piper Sandler increased their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Barclays reduced their price target on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating on the stock in a research report on Monday, April 7th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 2nd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Buy” and a consensus target price of $275.71.

Hedge Funds Weigh In On Becton, Dickinson and Company

Large investors have recently bought and sold shares of the company. Bank of Jackson Hole Trust acquired a new position in Becton, Dickinson and Company during the 4th quarter worth about $25,000. REAP Financial Group LLC grew its stake in Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 55 shares during the period. Sierra Ocean LLC acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. Picton Mahoney Asset Management grew its position in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 54 shares during the period. Finally, Nexus Investment Management ULC bought a new position in Becton, Dickinson and Company during the first quarter worth $34,000. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Richard Byrd sold 1,940 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total value of $436,325.40. Following the transaction, the executive vice president now directly owns 7,411 shares in the company, valued at $1,666,808.01. This trade represents a 20.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey William Henderson purchased 1,500 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, February 10th. The stock was acquired at an average cost of $233.62 per share, with a total value of $350,430.00. Following the transaction, the director now owns 8,015 shares in the company, valued at $1,872,464.30. This trade represents a 23.02 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 4,675 shares of company stock valued at $1,057,182. Corporate insiders own 0.36% of the company’s stock.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.